Skip to main content
. 2022 Feb 22;39(4):1754–1771. doi: 10.1007/s12325-022-02060-1

Fig. 1.

Fig. 1

Patient disposition flowchart. LA SSA long-acting somatostatin analogue, LAN lanreotide autogel, NETs neuroendocrine tumors, OCT octreotide long-acting release